DBV Technologies (NASDAQ:DBVT) Raised to Hold at StockNews.com

StockNews.com upgraded shares of DBV Technologies (NASDAQ:DBVT) from a sell rating to a hold rating in a report issued on Friday morning.

A number of other research firms have also issued reports on DBVT. JMP Securities upped their target price on shares of DBV Technologies from $10.00 to $15.00 and gave the company a “market outperform” rating in a report on Thursday, May 1st. HC Wainwright upped their price objective on shares of DBV Technologies from $7.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, May 5th.

DBV Technologies Price Performance

Shares of DBVT opened at $9.83 on Friday. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $10.12. The firm has a 50 day simple moving average of $6.91 and a 200-day simple moving average of $4.87. The stock has a market cap of $269.24 million, a price-to-earnings ratio of -2.18 and a beta of -0.66.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The company had revenue of $0.51 million for the quarter. On average, equities analysts expect that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.